Latest updates for INCY PCYC SGEN BMRN CEMP CYTK CYTR EBIO EXEL KYTH LPCN LXRX MDCO NBIX NBS OCRX OGXI OPK THLD THRX TSRO

May 02, 2015 No Comments by

Latest updates to the Company Pipeline Database for April 29-May 1 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary INCY 98.28 Ruxolitinib – JANUS 1 and JANUS 2 Cancer – Pancreatic Phase 3 Phase 3 data for JANUS 1 due 2016. JANUS 2 due at a later date PCYC 254.51 IMBRUVICA […]

Daily News Read more

CLDN fails Phase 2b trial + updates for week ending April 26 – AERI CNAT GNCA AMPE GWPH MDWD ONTX OTIC SGEN ATHX DSCO

Apr 26, 2015 No Comments by

Latest updates to the Company Pipeline Database for week ending April 26 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 12.87 Rhopressa Glaucoma Phase 3 Phase 3 Rocket 1 trial data released April 2015 did not meet endpoint. Rocket 2 data due 3Q 2015 CLDN 13.68 MYDICAR – CUPID […]

Daily News Read more

Updates for week ending February 20

Feb 20, 2015 No Comments by

Latest updates to the Company Pipeline Database for week ending February 20, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AGIO 106.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 trial to be initiated 1H 2015 2/21/2015 ARIA 8.06 Brigatinib – ALTA trial Anaplastic lymphoma kinase […]

Daily News Read more

Latest updates for TTHI NBIX OHRP GALE KMDA AMAG ANIK AMGN ANTH RGLS LJPC SGEN SGMO

Feb 12, 2015 No Comments

Latest updates to the Company Pipeline Database for February 9-11, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AMAG 40.05 Makena – single-dose (1 mL) vial Reduce the risk of preterm birth in women with a singleton pregnancy PDUFA FDA decision due 2Q 2015 2/12/2015 AMGN […]

Read more

SGEN Phase 3 AETHERA data due Monday. ALIM PSDV FDA Approval. ACRX NDA update + GLYC delay

Sep 27, 2014 No Comments

Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call and webcast on Monday, September 29, 2014, at 8:30 a.m. Eastern Time (ET) regarding top-line results from its ADCETRIS Phase 3 AETHERA clinical trial for Hodgkin lymphoma patients at risk of relapse following autologous stem cell transplant. Alimera Sciences, Inc. (NASDAQ: ALIM) and pSivida Corp. (NASDAQ: […]

Read more

Pipeline updates and news over the previous week from 20 companies.

Aug 03, 2014 No Comments

Pacira Pharmaceuticals, Inc.(NASDAQ: PCRX) noted that the FDA has set a PDUFA date of March 5, 2015 for the supplemental New Drug Application (sNDA) for a nerve block indication for EXPAREL. NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) said that their BAYnovation trial for viral conjunctivitis has been completed and top-line results are due in mid-August 2014. Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) maintained guidance that the pre-planned […]

Read more

Updates for GALE SCMP BLRX APPA RPTP ACOR RLYP INFI HALO ARNA CLVS SGEN ICPT GILD CUR MRK CYCC CRIS ACHN

Jan 13, 2014 No Comments

Curis, Inc.(NASDAQ:CRIS) provided an update noting that Phase 2 data of everolimus for Operable Nodular BCC (basal cell carcinoma) are due 1Q 2014. Their submission to the FDA regarding the partial clinical hold of CUDC-427 is due shortly. A Phase 2 trial of Debio 0932 is due to be to initiated in 2H 2014. Galena Biopharma (Nasdaq:GALE) announced it has […]

Read more

AEZS file NDA. IMGN fail Phase 2 trial. ECYT decision due Dec-Jan. ADHD data due Dec. KERX positive data + updates for STEM SGEN PTLA ISIS INSM ZGNX ITMN

Nov 06, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.39) announced that it has submitted a NDA for AEZS-130 for adult growth hormone deficiency (“AGHD”). ImmunoGen, Inc. (Nasdaq: IMGN $13.41) announced that it will discontinue their Phase 2 trail of IMGN901 for SCLC, following the recommendation from the Data Monitoring Committee (DMC) due to a higher rate of infection and […]

Read more

DVAX requires more safety data. AVEO CRL. CLVS offering. BDSI NDA due mid summer + SGEN EXAS AZN updates

Jun 11, 2013 No Comments

Dynavax Technologies Corporation (NASDAQ: DVAX) reported that following a meeting with the FDA regarding its Biologic License Application (BLA) for HEPLISAV,an adult hepatitis B vaccine, additional safety data would be required before they refile their BLA. This would most likely necessitate the need for a new trial. Clovis Oncology (NASDAQ:CLVS) announced that it has commenced an underwritten […]

Read more

AFFY CEO contract terminated. ACAD RMTI offerings. SGEN PDUFA date set + TTPH LGND PTN PRMD KBIO GENT updates

May 15, 2013 No Comments

Affymax, Inc. (NASDAQ:AFFY) announced in a filing that the contract of its CEO, John Orwin, has been terminated. This follows a company-wide restructuring plan by The Brenner Group, Inc, a restructuring firm assigned by Affymax. Rockwell Medical, Inc. (Nasdaq:RMTI) announced it intends to offer shares in an underwritten public offering. ACADIA Pharmaceuticals Inc. (ACAD) also  announced it intends to offer shares […]

Read more

Pipeline updates for ACHN BCRX BLRX CLVS RIGL INSM TRGT CBST INFI AEZS SCMP SGEN FURX EXEL FLML TSRX KERX ZIOP ISIS

May 08, 2013 No Comments

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) provided an update noting that interim RVR results from its Phase 2 ACH-3102 trials for the treatment of genotype 1 HCV are due in 3Q 2013 (-007 trial), followed by SVR results during 4Q 2013. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it plans to initiate a Phase 2 trial of BCX4161 in patients with hereditary angioedema, later in 2013 […]

Read more